Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy

• Published in: Journal of clinical medicine Vol. 13; no. 2; p. 566
• Main Authors: Chen, Yen-Fu, Hsu, Shih-Tien, Hwang, Sheau-Feng, Sun, Lou, Liu, Chih-Ku, Shih, Yu-Hsiang, Lu, Ting-Fang, Wang, Jun-Sing, Lu, Chien-Hsing
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Ascites; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Development and progression; Medical imaging; Metastasis; Mortality; Ovarian cancer; Patient outcomes; Patients; Radiation therapy; Relapse; Surgery; Womens health; Taiwan; maintenance therapy; epithelial ovarian cancer; chemotherapy; platinum-sensitive ovarian cancer; recurrent ovarian cancer
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13020566

(1) Background: Our aim was to evaluate the efficacy and adverse effects of maintenance chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer after second-line chemotherapy. (2) Methods: A total of 72 patients from a single institute who had been diagnosed with platinum-sensitive recurrent ovarian cancer and had experienced either complete or partial response after six cycles of second-line chemotherapy were divided into a standard group (n = 31) with six cycles or a maintenance group (n = 41) with more than six cycles. We then compared patient characteristics and survival outcomes between these two groups. (3) Results: In all patients, after primary management for the first recurrence, the maintenance group showed worse survival outcomes. Patients who had not undergone either surgery or radiotherapy were divided into complete response and partial response groups after six cycles of chemotherapy. In patients with partial response, maintenance chemotherapy led to a significant improvement in PFS (median, 3.6 vs. 6.7 months, p = 0.007), but no significant change in in OS. The median cycle number of maintenance chemotherapy was four. (4) Conclusions: Maintenance chemotherapy may still play an important role in patients with platinum-sensitive recurrent ovarian cancer, particularly in selected patient groups.